Raúl Martín Ruiz
Direktor/Vorstandsmitglied bei STAT-Dx Life SL
Ursprung des Netzwerks ersten Grades von Raúl Martín Ruiz
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona.
24
| Private Company | Investment Managers | 24 |
Anaconda Biomed SL
 Anaconda Biomed SL Medical SpecialtiesHealth Technology Anaconda Biomed SL manufactures healthcare devices. It develops catheters for mechanical thrombectomies. The company was founded by Marc Ribo and Ofir Arad and is headquartered in Barcelona, Spain.
9
| Holding Company | Medical Specialties | 9 |
CorWave SA
 CorWave SA Medical SpecialtiesHealth Technology CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France.
9
| Holding Company | Medical Specialties | 9 |
Medlumics SL
 Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.
8
| Holding Company | Medical Specialties | 8 |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
Synendos Therapeutics AG
 Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland.
6
| Holding Company | Medical Specialties | 6 |
STAT-Dx Life SL
 STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain.
4
| Subsidiary | Medical Specialties | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Raúl Martín Ruiz
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| TIGENIX NV | Medical Specialties | Director/Board Member Director of Finance/CFO | |
| ALMIRALL, S.A. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| INTEGRAGEN | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Analyst | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| University of Barcelona | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree | |
| University of Deusto | College/University | Masters Business Admin Masters Business Admin | |
| Ghent University | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| University of Lausanne | College/University | Graduate Degree Masters Business Admin | |
| Universitat Pompeu Fabra | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| SUPERSONIC IMAGINE | Medical Specialties | Director/Board Member Director/Board Member | |
| ESCP Europe Campus Paris | College/University | Undergraduate Degree Graduate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Private Equity Investor | |
Innogest SGR SpA
 Innogest SGR SpA Investment ManagersFinance Innogest SGR SpA (Innogest) is a private equity firm founded in 2005 by Claudio Giuliano and Marco Pinciroli. The firm is headquartered in Milan, Italy. | Investment Managers | Private Equity Investor Private Equity Investor | |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chairman Director of Finance/CFO | |
Sunstone Capital A/S
 Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Universidad Autónoma de Madrid | College/University | Doctorate Degree Undergraduate Degree | |
| EOS IMAGING | Medical Specialties | Chairman Chief Executive Officer | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Founder Director/Board Member | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree | |
| Instituto de Estudios Superiores de la Empresa | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Xeltis AG
 Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Chairman Director/Board Member Director/Board Member | |
| PIXIUM VISION | Medical Specialties | Director/Board Member Director/Board Member | |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member Director/Board Member | |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Nuevolution A/S
 Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Aelix Therapeutics SL
 Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
| ARCUS BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
LimFlow SA
 LimFlow SA Medical SpecialtiesHealth Technology LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member Director/Board Member | |
SpliceBio SL
 SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
NuMat Medtech SL
 NuMat Medtech SL Miscellaneous Commercial ServicesCommercial Services NuMat Medtech SL engages in the development of coating technology for dental and orthopedic bone implants. It offers solutions based on natural molecules that improves functionalities on implants. The company was founded by Marta Monjo and Joana M. Ramis in 2016 and is headquartered in Palma de Mallorca, Spain. | Miscellaneous Commercial Services | Chairman | |
Asabys Partners SGEIC SA
 Asabys Partners SGEIC SA Investment ManagersFinance Asabys Partners SGEIC SA (Asabys Partners) is an independent venture capital firm founded in 2019 by Clara Campàs-Moya and Josep Lluís Sanfeliu Benet. The firm is headquartered in Barcelona, Spain. | Investment Managers | Founder Private Equity Investor Private Equity Investor Private Equity Investor | |
| Kurma Partners /DE/ | Investment Managers | Private Equity Investor | |
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Frontier Medicines Corp.
 Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Sardona Therapeutics, Inc. | Director/Board Member |
Statistik
International
| Spanien | 17 |
| Frankreich | 9 |
| Vereinigte Staaten | 8 |
| Schweiz | 6 |
| Dänemark | 5 |
Sektoral
| Health Technology | 29 |
| Consumer Services | 12 |
| Finance | 7 |
| Commercial Services | 4 |
| Health Services | 2 |
Operativ
| Director/Board Member | 348 |
| Corporate Officer/Principal | 96 |
| Chairman | 74 |
| Private Equity Investor | 57 |
| Independent Dir/Board Member | 47 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Richard Ferrari | 43 |
| Søren Lemonius | 39 |
| Cristina Garmendia Mendizábal | 38 |
| Peter Andersen | 26 |
| Gérard Hascoët | 25 |
| Claudio Nessi | 25 |
| Philippe Boucheron | 24 |
| Emmanuelle Coutanceau | 21 |
| Olivier Litzka | 21 |
| Claudius Rumazza | 20 |
| Gérard Vaillant | 20 |
| Alan William O'Connell | 19 |
| Pamela Klein | 19 |
| Joël Jean-Mairet | 17 |
| Marie Meynadier | 17 |
- Börse
- Insiders
- Raúl Martín Ruiz
- Unternehmensverbindungen
